

# HYPO RESOLVE

**EASD**

European Association  
for the Study of Diabetes

## Hypo-RESOLVE consortium @EASD

### Monday, 19th September 2022

- 12:40–13:00 & Rory McCrimmon (UK): **Simplifying experiences through choice** (Golgi Hall)  
14:25–14:45
- 13:40–13:55 Julia Mader (AUT): **The bigger picture: once-weekly insulin and digital health solutions together** (Bernard Hall)
- 14:25–14:45 Rory McCrimmon (UK): **Simplifying experiences through choice** (Golgi Hall)
- 15:00–15:20 Julia Mader (AUT): **Going beyond glucose control: a new approach for T1D treatment** (Bernard Hall)

### Tuesday, 20th September 2022

- 11:45–12:45 **Short Oral Discussions Event A, SO 43 Glucose lowering agents**  
(All Halls, except Virchow Hall)
- 683 Comparing the rates and duration of sensor detected hypoglycaemia and patient reported hypoglycaemia based on diabetes type and awareness status: Hypo-METRICS trial; P.M. Divilly, G. Martine-Edith, Z. Mahmoudi, N. Zaremba, U. Søholm, F. Pouwer, S.A. Amiel, P. Choudhary, UK, Denmark

#### The diaTribe Foundation's Ninth Annual Panel Discussion: Solvable Problems in Diabetes 2022

Panelists: Stephanie Amiel, Julia Mader, 19:00, Eric Ericsonhallen, Stockholm, Sweden

**Register here:** <https://diatribe.app.neoncrm.com/np/clients/diatribe/eventRegistration.jsp?event=36&>

### Wednesday, 21st September 2022

- 14:30 **OP23 Are we too slow to outlaw the low?** (Doniach Hall)
- 135 Dishabituation with high intensity exercise improves hormonal and symptom responses to hypoglycaemia in people with type 1 diabetes and impaired awareness of hypoglycaemia C.M. Farrell, A.D. McNeilly, S.M. Hapca, T.W. Jones, P.A. Fournier, D. West, R.J. McCrimmon, UK, Australia
- 18:45–18:50 Rory McCrimmon (UK): **Timely Treatment Intensification—the Key to Better Glycemic Control** (Heding Hall)
- 19:10–19:15 Rory McCrimmon (UK): **Panel Discussion** (Heding Hall)
- 19:25–19:45 Pratik Choudhary (UK): **Tempo™: A Connected Pen System** (Jacobsohn Hall)
- 19:45–20:05 Pratik Choudhary (UK): **Practical Application of Lyumjev® and Tempo™** (Jacobsohn Hall)

# HYPO RESOLVE

**EASD**

European Association  
for the Study of Diabetes

## Hypo-RESOLVE consortium @EASD

### Thursday, 22nd September 2022

- 13:00–13:45** EASD e-Learning session ‘Technology and type 1 diabetes’; Pratik Choudhary (Chair), Julia Mader and Thomas Danne (Speaker) (Virchow Hall)
- 13:15–14:15** Short Oral Discussions Event F, SO 48 Hypoglycaemia: hip hip hooray yet to come (All Halls, except Virchow Hall)
- 625 Hypo-metrics: associations between hypoglycaemia awareness, blood glucose range and patient-reported hypoglycaemia symptoms in type 1 diabetes; G. Martine-Edith, P. Divilly, N. Zaremba, U. Søholm, Z. Mahmoudi, M. Gomes, M. Broadley, J. Speight, S.A. Amiel, F. Pouwer, P. Choudhary, Hypo-RESOLVE Consortium, UK, Denmark, Australia
  - 628 Patterns of sensor-detected hypoglycaemia in long-duration CGM data from a diabetes registry; P.M. Baumann, D.A. Hochfellner, M. Cigler, L. Roubik, T. Pöttler, J.K. Mader, on behalf of the Hypo-RESOLVE Consortium, Austria
  - 632 Sustained pro-inflammatory effects following hypoglycaemia in people with type 1 or type 2 diabetes; J.I. Van Heck, C.E. Verhulst, T.W. Fabricius, R. Stienstra, C.J. Tack, U. Pedersen-Bjergaard, B.E. De Galan, Hypo-RESOLVE Consortium, Netherlands, Denmark
- 13:15–14:15** Short Oral Discussions Event F, SO 54 Making sense out of sensors and data (All Halls, except Virchow Hall)
- 679 Introduction of isCGM with glucose alarms to regular isCGM users under real-life conditions: What is the benefit?; D.A. Hochfellner, P.M. Baumann, A.K. Reinhard, J.K. Mader, Austria
  - 681 Comparison between duration and nadir of symptomatic and asymptomatic sensor-detected hypoglycaemia in people with type 1 diabetes; M.M. Gomes, Z. Mahmoudi, G. Mathine-Edith, P. Divilly, N. Zaremba, U. Søholm, M. Broadley, F. Pouwer, S.A. Amiel, P. Choudhary, Denmark, UK, Australia

### Friday, 23rd September 2022

- 09:45–10:45** OP 39 Too little sugar is also bad: understanding hypoglycaemia (Golgi Hall)
- 226 Molecular investigations of defective hypoglycaemia counter-regulation in a murine model of type-2 diabetes: a multi-omics study; J. Castillo-Armengol, A. Rodriguez Sanchez-Archidona, C. Fledelius, F. Marzetta, B. Thorens, Denmark, Switzerland

[www.hypo-resolve.eu](http://www.hypo-resolve.eu)



The HypoResolve project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation (IDF), and The Leona M. and Harry B. Helmsley Charitable Trust.